Dan Schell, Chief Editor and Clinical Leader at Life Science Connect, shared a post on LinkedIn:
“In 2021, American Society of Clinical Oncology (ASCO) made the following 3 recommendations to improve trial site feasibility assessments (FAs):
1. implement a streamlined and uniform FA process across trials and sponsors
2. minimize and standardize questions
3. leverage technology to centralize FAs, facilitate communications, and reduce redundancies.
Have we made enough improvements since then?”